In addition to a news review and glimpses on LISAvienna’s services, you will find information on two major investments: Vienna succeeded in convincing the world-renowned pharma and biotech company Boehringer Ingelheim to invest about half a billion euros into production facilities in Vienna. In addition, the collaboration of the Medical University of Vienna and the Vienna General Hospital AKH has been brought to the next level – some 2.2 billion euros will be invested until 2030.
LISAvienna also provides you with a compact overview on clinical stage development projects from selected dedicated biotech companies in Vienna which focus on infectious diseases. Another article informs you on innovative companies you need to know when it comes to electromechanical medical devices.